Skip to main content
x

Recent articles

Allogene finds a way forward for allogeneic Car-T

After setbacks, cema-cel might have a path to approval in lymphoma.

SGO 2026 – GSK bucks the B7-H4 trend

The group impresses in ovarian and endometrial cancers.

Ideaya’s darovasertib plan comes together

Optimum-02 virtually replicates phase 1, and a filing will follow.

Replimune’s fight with the FDA deepens

The oncolytic virus vuso-vec is slapped with its second CRL.

Gilead is next into target degradation

After opting in last year, Gilead picks up Kymera's KT-200.

Revealed: Merck’s double bet on TROP2

MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.